Pharmacist-managed titration of urate-lowering therapy to streamline gout management

被引:8
作者
Huang, Irvin J. [1 ]
Liew, Jean W. [2 ]
Morcos, Meredith B. [3 ]
Zuo, Silu [4 ]
Crawfords, Carol [5 ]
Bays, Alison M. [2 ]
机构
[1] Univ Washington, Dept Med, Boise, ID USA
[2] Univ Washington, Dept Med, Div Rheumatol, Seattle, WA 98195 USA
[3] Virginia Mason Med Ctr, Rheumatol, Seattle, WA 98101 USA
[4] Univ Washington, Pharm, Seattle, WA 98195 USA
[5] Harborview Med Ctr, Pharm, Seattle, WA USA
基金
美国国家卫生研究院;
关键词
Crystal arthropathies; Hyperuricemia; Gout; Patient compliance; US GENERAL-POPULATION; CARE; ADHERENCE; HYPERURICEMIA; PREVALENCE; GUIDELINES; HEALTH; TARGET; TREAT;
D O I
10.1007/s00296-019-04333-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The treat-to-target approach for serum uric acid is the recommended model in gout management according to the 2012 American College of Rheumatology (ACR) guidelines. Adherence to urate-lowering therapy (ULT) can be difficult for patients due to barriers, which include medication burden, financial hardship, and lack of medical literacy. Our aim was to create a pharmacist-managed referral for the titration of ULT to target serum uric acid (sUA) levels in a complex patient population. We utilized a clinical database to query patients seen at a rheumatology clinic over a 12-month period with an ICD-10 diagnosis for gout. The referral criteria were indications for ULT per the 2012 ACR guidelines. Rheumatology providers, consisting of attendings, fellows, and a physician assistant, were asked to refer the identified patients to the pharmacist-managed titration program. The intervention group consisted of 19 referred patients and the control group consisted of 28 non-referred patients. The baseline sUA (median (IQR)) at the time of referral was 8.8 (2) mg/dL for the intervention group and 7.6 (2.8) mg/dL for the control group (p = 0.2). At the end of the study period, the sUA was 6.1 (1.4) mg/dL for the intervention group and 6.8 (3.2) mg/dL for the control group (p = 0.08). At the end of the study period, 6 of 19 (32%) intervention group and 7 of 28 (25%) control group were at goal (p = 0.3). A newly instituted pharmacist-managed titration program was able to achieve lower average sUA levels in referred patients compared to demographically similar individuals who received standard gout management.
引用
收藏
页码:1637 / 1641
页数:5
相关论文
共 50 条
  • [31] Improving adherence to urate-lowering therapy in people living with gout
    Coleshill, Matthew J.
    Aung, Eindra
    Nguyen, Amy D.
    Stocker, Sophie L.
    Baysari, Melissa T.
    Kamel, Bishoy
    Schulz, Marcel
    McLachlan, Andrew J.
    Day, Richard O.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (04) : 542 - 544
  • [32] Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review
    Tabi-Amponsah, Adwoa Dansoa
    Stewart, Sarah
    Hosie, Graham
    Stamp, Lisa K.
    Taylor, William J.
    Dalbeth, Nicola
    PHARMACEUTICALS, 2023, 16 (06)
  • [33] Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout
    Helget, Lindsay N.
    O'Dell, James R.
    Newcomb, Jeff A.
    Androsenko, Maria
    Brophy, Mary T.
    Davis-Karim, Anne
    England, Bryant R.
    Ferguson, Ryan
    Pillinger, Michael H.
    Neogi, Tuhina
    Palevsky, Paul M.
    Wu, Hongsheng
    Kramer, Bridget
    Mikuls, Ted R.
    LANCET RHEUMATOLOGY, 2023, 5 (12) : e706 - e706
  • [34] Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout
    Topless, Ruth
    Noorbaloochi, Siamak
    Merriman, Tony R.
    Singh, Jasvinder A.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2022, 56
  • [35] The Effects of Pharmacological Urate-Lowering Therapy on Cardiovascular Disease in Older Adults with Gout
    Gerritsen, Martijn
    Nurmohamed, Mike T.
    DRUGS & AGING, 2024, 41 (04) : 319 - 328
  • [36] Urate-Lowering Therapy: Current Options and Future Prospects for Elderly Patients with Gout
    Stamp, Lisa K.
    Chapman, Peter T.
    DRUGS & AGING, 2014, 31 (11) : 777 - 786
  • [37] Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients
    te Kampe, Ritch
    Boonen, Annelies
    Jansen, Tim
    Janssen, Matthijs
    de Vries, Hein
    van Durme, Caroline
    RMD OPEN, 2022, 8 (01):
  • [38] COMPARISON OF URATE-LOWERING EFFICACY AND SAFETY OF FEBUXOSTAT AND ALLOPURINOL IN GOUT PATIENTS
    Singh, Gajendera
    Kumar, Hemant
    Soni, Udit
    Tyagi, Shikhar
    Aggarwal, Kritika
    Verma, Kavita
    Kumar, Sumit
    HETEROCYCLIC LETTERS, 2016, 6 (01): : 133 - 147
  • [39] Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate-Lowering Therapy in Ontario, Canada
    Kwok, Timothy S. H.
    Kuriya, Bindee
    Hawker, Gillian
    Li, Ping
    Choy, Gregory
    Widdifield, Jessica
    ARTHRITIS CARE & RESEARCH, 2023, 75 (12) : 2463 - 2471
  • [40] Depressive Symptoms and the Effectiveness of a Urate-Lowering Therapy in a Clinical Trial
    Mrug, Sylvie
    Orihuela, Catheryn
    Rahn, Elizabeth
    Mudano, Amy
    Foster, Jeffrey
    Saag, Kenneth
    Gaffo, Angelo
    ACR OPEN RHEUMATOLOGY, 2020, 2 (12) : 710 - 714